Scientific Library
- Acute Coronary Syndrom
- ASCVD Prevention
- Bifurcation Stenting
- Cardio-Oncology
- Congestive Heart Failure
- DAPT Duration
- Drug Coated Balloon
- Fractional Flow Reserve
- IVUS Guidance
- Optical Coherence Tomography
- Pulmonary Hypertension
- Rotational Atherectomy
- Shear Stress
- Stenting Left Main
- Transcatheter Aortic Valve Replacement
- Percutaneous LAA Occlusion
- Mitral/Tricuspid Valvular Disease
- Other Relevant Articles
-
Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trialCollet JP, Silvain J, ARCTIC investigators. -
Higher neutrophil-to-lymphocyte ratio (NLR) increases the risk of suboptimal platelet inhibition and major cardiovascular ischemic events among ACS patients receiving dual antiplatelet therapy with ticagrelorM Verdoiaab, M Nardinb, R Gioscia et al.
-
Dual antiplatelet therapy (PEGASUS) vs. dual pathway (COMPASS): a head-to-head in vitro comparisonCR Clifford, RG Jung, B Hibbert et al.
-
Ticagrelor versus clopidogrel in patients with acute coronary syndromesWallentin L, PLATO Investigators, Thorsén M.
-
Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trialHelft G, Steg PG, OPTImal DUAL Antiplatelet Therapy Trial Investigators.
-
Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trialJ Silvain, B Lattuca, ALPHEUS investigators et al.
-
'Ticagrelor alone vs. dual antiplatelet therapy from 1 month after drug-eluting coronary stenting among patients with STEMI': a post hoc analysis of the randomized GLOBAL LEADERS trialAS Gamal, H Hara, PW Serruys et al.
-
Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trialColombo A, Chieffo A, Frasheri A et al.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
